Fraiser Kansteiner is a staff writer at Fierce Pharma. He covers a range of topics including pharmaceutical manufacturing, drug delivery, and the impacts of COVID-19, with a focus on medicine and healthcare, pharmaceuticals, and public health. Fraiser's work has been featured in NewsBreak, Biotech, Fierce Pharma, and RealClearHealth.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Fraiser Kansteiner's coverage primarily revolves around the healthcare and pharmaceutical industry, with a focus on regulatory announcements, press releases, and data citations. To effectively reach out to Fraiser, consider providing insights into pharmaceutical industry trends, drug developments or FDA regulations. Sources with access to unpublished data or exclusive information about pivotal events within the healthcare sector may be of particular interest to him.
Since Fraiser does not specify any geographic focus in his articles, it is likely that he covers global pharmaceutical news and would be interested in international perspectives on key issues within the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Fraiser Kansteiner
Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.'s HPV vaccine Gardasil to win confirmation as Health and Human Services secretary last year, a quartet of lawmakers are raising fresh concerns about the benefits a recent Merck settlement may confer upon Kennedy's family.
By: Fraiser Kansteiner
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing
By: Fraiser Kansteiner
In hopes of challenging Incyte's topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo (NSV).
By: Fraiser Kansteiner
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
By: Fraiser Kansteiner
Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, securing a U.S.
By: Fraiser Kansteiner
'Tis the season to resolve long-standing litigation in the U.S. A week after Johnson & Johnson moved to resolve claims that its Johnson's
By: Fraiser Kansteiner
With Bayer's pharma sales growth lagging behind its crop science and consumer health divisions in the second quarter, analysts once again raised the possibility of major changes to the German conglomerate's group structure.
By: Fraiser Kansteiner
As Amgen's flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular risk reduction data last year, the company is confident it can keep that momentum running well past the end of the decade.
By: Fraiser Kansteiner
Novo's Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company's injectable GLP-1.
By: Fraiser Kansteiner
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.
